Katherine M. Bennett, Pharm.D.

Publications

1. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010 Apr;62(4):1060-8.
2. Koller E., Schneider B., Bennett K., Dubitsky G. "Clozapine-Associated Diabetes." Am. J. Med. 111:716-23 (2001).
3. Bennett K.M., Rosen G. "Cyclic Total Parenteral Nutrition." Nutr. Clin. Pract., 5:163-5 (1990).

Presentations

1. Terkeltaub R, Furst D, Bennett K, Kook K, Davis MW. Low dose (1.8 mg) vs high dose (4.8 mg) oral colchicine regimens in patients with acute gout flare in a large, multicenter, randomized, double-blind, placebo-controlled, parallel group study. Presented at American College of Rheumatology (ACR) annual congress. October 28, 2008. San Francisco, CA. Presentation 1944.
2. Terkeltaub R, Furst DE, Bennett K, Kook K, Crockett RS, Davis MW. Colchicine efficacy assessed by time to 50% reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the AGREE trial. Presented American College of Rheumatology (ACR) annual congress. October 19, 2009. Philadelphia, PA. Presentation 1103.
3. Terkeltaub R, Furst DE, Kook K, Bennett K, Arnold K, Davis MW. Maximal plasma concentrations of low-dose vs high-dose colchicine are similar but total exposure is dose dependent: implications for safe administration of colchicine to treat acute gout flare. Presented at American College of Rheumatology (ACR) annual congress. October 19, 2009. Philadelphia, PA. Presentation 1108.

Texts

1. USP DI 1995-1998. Drug Information for the Healthcare Professional Advice for the Patient. United States Pharmacopeial Convention, Inc.

Responsible for the development of new drug monographs and for the revision of 45 existing drug monographs related to the practice of respiratory medicine.